Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNicole R. LeBoeufAEAshleigh Eberly-Puleo

Discussion

Loading...

Member takes

Overview

Phase 2 trial demonstrates TAG-AZA-VEN improves outcomes in BPDCN with manageable toxicity, suggesting a promising treatment approach.

Key Points

  • To evaluate the efficacy and safety of TAG-AZA-VEN triplet therapy in patients with BPDCN.
  • Conducted a phase 2 trial among patients with previously untreated or relapsed/refractory BPDCN.
  • Administered TAG (tagraxofusp), AZA (azacitidine), and VEN (venetoclax) in 28-day cycles.
  • Evaluated response criteria including bone marrow and skin assessments alongside CNS evaluation.
  • 88% of 1L patients achieved composite CR, with median follow-up of 20.4 months.
  • In R/R cohort, 64% achieved composite CR, with median OS of 8.4 months.
  • Treatment-related adverse events were similar to prior studies, with manageable capillary leak syndrome rates.

Cite This Study

LeBoeuf et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d402https://doi.org/10.1182/blood-2025-653
View Full Paper
Ask AI
Bookmark
Share